Trial Profile
A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Epcoritamab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms EPCORE NHL-1
- Sponsors Genmab
- 25 Mar 2024 Planned End Date changed from 1 Apr 2029 to 1 Jan 2029.
- 25 Mar 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Mar 2025.
- 25 Mar 2024 Status changed from recruiting to active, no longer recruiting.